Pharmaceuticals in China

Published Date: 17/01/2011
Category: Therapies & Markets

Research Report Decription

Sample Pages:

Click here (PDF)

Pharmaceuticals in China industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the China pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

• Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in China
• Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in China
• Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
• Add weight to presentations and pitches by understanding the future growth prospects of the China pharmaceuticals market with five year forecasts
• Macroeconomic indicators provide insight into general trends within the China economy

Key Questions Answered:

• What was the size of the China pharmaceuticals market by value in 2010?
• What will be the size of the China pharmaceuticals market in 2015?
• What factors are affecting the strength of competition in the China pharmaceuticals market?
• How has the market performed over the last five years?

• Who are the top competitiors in China's pharmaceuticals market?

Companies Mentioned:

AstraZeneca, Pfizer, Yangtze River Pharmaceutical Group

Paper Highlights:

• The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
• The Chinese pharmaceuticals market had total revenues of $43.1 billion in 2010, representing a compound annual growth rate (CAGR) of 18.5% for the period spanning 2006-2010.
• The performance of the market is forecast to decelerate, with an anticipated CAGR of 15.9% for the five-year period 2010-2015, which is expected to drive the market to a value of $90.2 billion by the end of 2015.
• Yangtze River Pharmaceutical Group is the leading player in the Chinese pharmaceuticals market, generating a 2.2% share of the market's value.